Literature DB >> 8626514

Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.

S Stefansson1, D A Lawrence, W S Argraves.   

Abstract

Thrombin is a multifunctional protein that has both proteinase and growth factor-like activities. Its regulation is largely mediated by interaction with a host of inhibitors including antithrombin III (ATIII), heparin cofactor II (HCII), alpha2-macroglobulin (alpha2-M), protease nexin I, and plasminogen activator inhibitor-1 (PAI-1). ATIII, HCII, and alpha2-M are all abundant in blood and can inactivate blood-borne thrombin leading to rapid hepatic clearance of the thrombin-inhibitor complex. PAI-1 alone, a poor solution phase inhibitor of thrombin, can efficiently inhibit thrombin in the presence of native vitronectin (VN). In this study, active thrombin was found to be efficiently endocytosed and degraded by cultured pre-type II pneumocyte cells, and both processes could be blocked by polyclonal antibodies to PAI-1. When the relative efficiency of cellular endocytosis of thrombin in complex with a number of inhibitors was examined, 125I-thrombin-PAI-1 complexes were most efficiently cleared compared to 125I-thrombin in complex with the serpins ATIII, HCII, alpha1-proteinase inhibitor, or d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone. Low density lipoprotein receptor-related proteins 1 (LRP) and 2 (gp330/megalin) mediate the endocytosis of thrombin-PAI-1, since antagonists of receptor function such as LRP-1 and LRP-2 antibodies and the 39-kDa receptor-associated protein blocked 125I-thrombin-PAI-1 endocytosis and degradation. The LRP-mediated clearance of exogenously added 125I-thrombin by cultured cells was found to be enhanced 5-fold by inclusion of wild-type PAI-1 but by only 2-fold when a mutant form of PAI-1 that is unable to bind VN was included. This wild-type PAI-1 enhancement of 125I-thrombin clearance was found to occur only in the presence of native VN and not with its conformationally altered form. The results highlight a novel mechanism for cellular clearance of thrombin involving native VN promoting the interaction of thrombin and PAI-1 and the subsequent endocytosis of the complex by LRP-1 or LRP-2. This pathway is potentially important for the regulation of the potent biological activities of thrombin, particularly at sites of vascular injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626514     DOI: 10.1074/jbc.271.14.8215

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  Biochem J       Date:  2016-08-01       Impact factor: 3.857

2.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

Review 3.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 4.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

5.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Authors:  Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  PAI-1 inhibits neutrophil efferocytosis.

Authors:  Young-Jun Park; Gang Liu; Emmanuel F Lorne; Xia Zhao; Jing Wang; Yuko Tsuruta; Jaroslaw Zmijewski; Edward Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

7.  Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling.

Authors:  Amandine Cartier-Michaud; Michel Malo; Cécile Charrière-Bertrand; Gilles Gadea; Christelle Anguille; Ajitha Supiramaniam; Annick Lesne; Franck Delaplace; Guillaume Hutzler; Pierre Roux; Daniel A Lawrence; Georgia Barlovatz-Meimon
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

8.  uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium.

Authors:  Ceri E Stewart; Hala S Nijmeh; Christopher E Brightling; Ian Sayers
Journal:  Thorax       Date:  2011-12-03       Impact factor: 9.139

Review 9.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

Review 10.  A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.

Authors:  Gael B Morrow; Claire S Whyte; Nicola J Mutch
Journal:  Front Cardiovasc Med       Date:  2021-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.